Fasting Insulin as an Independent Predictor of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Severity

被引：0
|
作者：
Harrison, Stephen A.
Dubourg, Julie
Jeannin, Sophie
Colca, Jerry R.
Ratziu, Vlad
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1582-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1582-P
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Metabolic Bariatric Surgery for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Scoping Review of Biomarker and Histology Changes
    Shah, A.
    Mohammadi, A.
    Haq, A.
    Walji, D.
    Zevin, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2025, 73 (01) : 297 - 299
  • [22] Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis
    Li, Xincheng
    Ayada, Ibrahim
    Li, Pengfei
    Pan, Qiuwei
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 108 - 109
  • [23] Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis
    Francque, Sven M.
    Vonghia, Luisa
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (12): : 1066 - 1067
  • [24] Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1701):
  • [25] Prediction of metabolic dysfunction-associated steatohepatitis resolution
    Loomba, Rohit
    Amangurbanova, Maral
    Bettencourt, Ricki
    Madamba, Egbert
    Siddiqi, Harris
    Richards, Lisa
    Gottwald, Mildred D.
    Feng, Shibao
    Margalit, Maya
    Huang, Daniel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S522 - S523
  • [26] Dulaglutide Improves Metabolic Dysfunction-Associated Steatohepatitis (MASH), but Not Atherosclerosis, Independent of Weight Loss in Middle-Age LDLR-/- Mice
    Shantaram, Dharti
    Rima, Xilal Y.
    Bradley, David
    Liu, Joey Z.
    Wright, Valerie P.
    Amari, Anastasiia
    Rottinghaus, Joseph
    Fernandes, Jaden M.
    Hsueh, Willa
    DIABETES, 2024, 73
  • [27] Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression
    Maretti-Mira, Ana C.
    Salomon, Matthew P.
    Chopra, Shefali
    Yuan, Liyun
    Golden-Mason, Lucy
    BIOMEDICINES, 2024, 12 (05)
  • [28] Role of Saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in nondiabetic patients: a prospective observational study
    Kumar, Jata Shankar
    Bhardwaz, Priyanshu
    Kar, Premashis
    JOURNAL OF HEPATOLOGY, 2024, 80 : S609 - S610
  • [29] Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
    Lam, Brian P.
    Bartholomew, Jessica
    Bau, Sherona
    Gilles, Hochong
    Keller, Andrea
    Moore, Ann
    Nader, Khalil
    Richards, Lisa
    Henry, Linda
    Younossi, Zobair M.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2025, 59 (04) : 298 - 309
  • [30] MACHINE LEARNING MODELS FOR PREDICTING METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE GENERAL UNITED STATES POPULATION
    Khalid, J.
    Aparasu, R. R.
    VALUE IN HEALTH, 2024, 27 (06) : S268 - S268
12345